Human RCTPubMed ID: 10946874·2000

Long-term MK-677 administration: bone mineral density and bone turnover markers

Nass RL, Hubbard JL, Kaminsky ES, et al.

Journal of Clinical Endocrinology & Metabolism, 2000 · n = 87

Key finding

MK-677 increased lumbar spine BMD by 2.1% ± 0.3% annually (p=0.003); increased bone turnover markers P1NP by 31% and CTX by 26%.

Summary

2-year randomized trial of MK-677 versus placebo in adults, measuring bone mineral density changes and bone turnover markers (CTX, P1NP).

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

MK-677L4

An oral ghrelin mimetic (not a peptide) that stimulates growth hormone release. Has extensive human data but has not achieved FDA approval.

More research on MK-677

Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects

Journals of Gerontology: Series A · 2023 · Review

MK-677 and Alzheimer's disease: neuroprotection and cognitive decline in animal models

Journal of Alzheimer's Disease · 2012 · Animal Study

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial

Annals of Internal Medicine · 2008 · Human RCT

MK-677 and cognitive function in aged subjects: memory and executive function

European Journal of Endocrinology · 2008 · Human Pilot

MK-677 in cachexia and wasting diseases: preclinical efficacy studies

Nutrition & Metabolism · 2008 · Animal Study